Skip to Content

Posts tagged with "The Dark Side"

  • Biological News

    Stem Cell Politics

    There have been complaints that something is going wrong in the publication of stem cell research. This isn’t my field, so I don’t have a lot of inside knowledge to share, but there appear to have been a number of researchers charging that journals (and their reviewers) are favoring some research teams over others: The… Read More
  • Cardiovascular Disease

    Steve Nissen’s Meeting with GSK

    Well, this is interesting. Back when Steve Nissen was about to publish his meta-analysis on the safety of Avandia (rosigiltazone), he met with several GlaxoSmithKline executives before the paper came out. At the time, GSK was waiting on data from the RECORD study, which was trying to address the same problem (unconvincingly, for most observers… Read More
  • Current Events

    Here’s a Business Plan For You

    On another front, we now have an ex-BMS associate scientist who’s apparently been arrested for stealing company materials in preparation for starting his own company back in India. I presume he was planning to get into the advanced pharmaceutical intermediates business (or perhaps the biotech end of it), using as much proprietary information… Read More
  • Analytical Chemistry

    Sequenom: Strike Up the Music, Bring On the Cream Pies

    Now here’s a weird one. The San Diego diagnostics company Sequenom came up with a non-invasive test for Down’s Syndrome, and sold it to another outfit, Xenomics, for development. Update: I’ve got this transfer backwards – Xenomics licensed some of its nucleic acid technology to Sequenom, and has now regretted it. But late la… Read More
  • Biological News

    Extortion, Retractions, And More

    Now here’s a strange tale, courtesy of Science magazine, about some retracted work from Peter Schultz’s group at Scripps. Two papers from 2004 detailed how to incorporate glycoslylated amino acids (glucosamine-serine and galactosamine-threonine) directly into proteins. These featured a lot of work from postdoc Zhiwen Zhang (who later wa… Read More
  • Analytical Chemistry

    GE Healthcare’s Idiotic Libel Suit

    Courtesy of Pharmalot (and my mail!), I note this alarming story from London. GE Healthcare makes a medical NMR contrast agent, a gadolinium complex marketed under the name of Omniscan. (They picked it up when they bought Amersham a few years ago). Henrik Thomsen, a Danish physician had noted what may be an association with… Read More
  • Analytical Chemistry

    Faking X-Ray Structures. . .For Fun? Or Profit? Or What?

    Well, this isn’t good: an ex-researcher at the University of Alabama-Birmingham has been accused of faking several X-ray structures of useful proteins – dengue virus protease, taq polymerase, complement proteins from immunology, etc. There have been questions surrounding H. M. Krishna Murthy’s work for at least a couple of years n… Read More
  • Business and Markets

    Pfizer’s Pearl River Layoffs

    Pfizer’s rounds of layoffs after the Wyeth merger are continuing, and look to go on for some time. A reader in New York state sends along word that there’s been some controversy over the cuts at the Pearl River site. New York law requires a company to give both the state (and employees) 90 days… Read More
  • Current Events

    Climategate and Scientific Conduct

    Everyone has heard about the “Climategate” scandal by now. Someone leaked hundreds of megabytes of information from the University of East Anglia’s Climatic Research Unit, and the material (which appears to be authentic) is most interesting. I’m not actually going to comment on the climate-change aspect of all this, though.… Read More
  • Clinical Trials

    Massaging the Data for Neurontin?

    There’s a disturbing article out at the New England Journal of Medicine on studies conducted on Neurontin (gabapentin) for various unapproved indications. Parke-Davis (and later Pfizer) looked at a wide range of possible indications for the drug – migraine, neuropathic pain, bipolar disorder, and more. That in itself isn’t unusual… Read More